Daily Stock Opinions and Ratings

Opinions

Larry Berman CFA, CMT, CTA Aptose Biosciences APS-T BUY ON WEAKNESS Jul 21, 2003

Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.

Larry Berman CFA, CMT, CTA

Unlock Rating

$1.180

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.

BUY

A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.

DON'T BUY

Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.

WEAK BUY

Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.

DON'T BUY

Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.

BUY

One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.

BUY

A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.

SELL

At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.

RISKY

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

PARTIAL BUY

Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Larry Berman CFA, CMT, CTA Aptose Biosciences APS-T BUY ON WEAKNESS Jul 21, 2003

You might be interested:

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Aptose Biosciences(APS-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights